Name of the medicinal product

Cimetidine Tablets USP 200mg Taj Pharma
Cimetidine Tablets USP 400mg Taj Pharma
Cimetidine Tablets USP 800mg Taj Pharma

Qualitative and quantitative composition

a) Cimetidine Tablets USP 200mg Taj Pharma
Each film-coated tablet contains:
Cimetidine USP 200mg
Excipients q.s

b) Cimetidine Tablets USP 400mg Taj Pharma
Each film-coated tablet contains:
Cimetidine USP 400mg
Excipients q.s

c) Cimetidine Tablets USP 800mg Taj Pharma
Each film-coated tablet contains:
Cimetidine USP 800mg
Excipients q.s

For a full list of excipients, see section 6.1.

Pharmaceutical form

Film-coated tablet.

Clinical particulars

4.1 Therapeutic indications

Cimetidine is a histamine H₂-receptor antagonist which rapidly inhibits both basal and stimulated gastric secretion of acid and reduces pepsin output.

Cimetidine is indicated in the treatment of duodenal and benign gastric ulceration, including that associated with non-steroidal anti-inflammatory agents, recurrent and stomal ulceration , oesophageal reflux disease and other conditions where reduction of gastric acid by Cimetidine has been shown to be beneficial: persistent dyspeptic symptoms with or without ulceration, particularly meal-related upper abdominal pain, including such symptoms associated with non-steroidal anti-inflammatory agents; the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients ; before general anaesthesia in patients thought to be at risk of acid aspiration (Mendelson’s Syndrome), particularly obstetric patients during labour ; to reduce malabsorption and fluid loss in the short bowel syndrome; and in pancreatic insufficiency to reduce degradation of enzyme supplements. Cimetidine is also recommended in the management of the Zollinger-Ellison syndrome.

4.2 Posology and method of administration

The total daily dose by any route should not normally exceed 2.4g. Dosage should be reduced in patients with impaired renal function (see Special warnings and precautions for use)

Posology

Adults:

Oral: The usual dosage is 400mg twice a day, with breakfast and at bedtime. For patients with duodenal or benign gastric ulceration, a single daily dose of 800mg at bedtime is recommended. Other effective regimens are 200mg three times a day with meals and 400mg at bedtime (1.0g/day) and, if inadequate, 400mg four times a day (1.6g/day), also with meals and at bedtime.

Symptomatic relief is usually rapid. Treatment should be given initially for at least four weeks (six weeks in benign gastric ulcer, eight weeks in ulcer associated with continued non-steroidal anti-inflammatory agents) even if symptomatic relief has been achieved sooner. Most ulcers will have healed by that stage, but those which have not will usually do so after a further course of treatment.

Treatment may be continued for longer periods in those patients who may benefit from reduction of gastric secretion and the dosage may be reduced as appropriate to 400mg at bedtime or 400mg in the morning and at bedtime. In patients with benign peptic ulcer disease who have responded to the initial course, relapse may be prevented by continued treatment, usually with 400mg at bedtime; 400mg in the morning and at bedtime has also been used.

In oesophageal reflux disease, 400 mg four times a day, with meals and at bedtime, for four to eight weeks is recommended to heal oesophagitis and relieve associated symptoms. In patients with very high gastric acid secretion (e.g. Zollinger-Ellison syndrome) it may be necessary to increase the dose to 400mg four times a day or in occasional cases further. Since Cimetidine may not give immediate symptomatic relief, antacids can be made available to all patients until symptoms disappear.

In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients, doses of 200 – 400mg can be given every four to six hours by the oral route.

In patients thought to be at risk of acid aspiration syndrome, an oral dose of 400mg can be given 90-120 minutes before induction of general anaesthesia or, in obstetric practice, at the start of labour. While such a risk persists, a dose of up to 400mg may be repeated (parenterally if appropriate) at four hourly intervals as required up to the usual daily maximum of 2.4g.

Cimetidine syrup should not be used. The usual precautions to avoid acid aspiration should be taken.

In the short bowel-syndrome e.g. following substantial resection for Crohn’s disease, the usual dosage range (see above) can be used according to individual response.

To reduce degradation of pancreatic enzyme supplements, 800-1600mg a day may be given, according to response, in four divided doses, one to one and a half hours before meals.

Elderly:

The normal adult dosage may be used unless renal function is markedly impaired (see section 4.4).

Paediatric population:

Experience in children is less than that in adults. In children more than one year old, Cimetidine 25-30mg/kg body weight per day in divided doses may be administered by oral route.

The use of Cimetidine in infants under one year old is not fully evaluated, 20mg/kg body weight per day in divided doses has been used.

Method of administration

For oral administration.

4.3 Contraindications

Hypersensitivity to Cimetidine or to any other of the tablet ingredients listed (see section 6.1).

4.4 Special warnings and precautions for use

Dosage should be reduced in patients with impaired renal function according to creatinine clearance. The following doses are suggested: Creatinine clearance of 0 to l5ml per minute, 200mg twice a day; 15 to 30ml per minute, 200mg three times a day; 30 to 50ml per minute, 200mg four times a day; over 50 ml per minute, normal dosage. Cimetidine is removed by haemodialysis, but not to any significant extent by peritoneal dialysis.

Clinical trials over six years’ continuous treatment and more than 15 years’ widespread use have not revealed unexpected adverse reactions related to long-term therapy.

The safety of prolonged use is not fully established and care should be taken to observe periodically patients given prolonged treatment.

Care should be taken that patients with a history of peptic ulcer, particularly the elderly, being treated with Cimetidine and a non-steroidal anti-inflammatory agent are observed regularly.

Before initiating therapy with this preparation for any gastric ulceration, malignancy should be excluded by endoscopy and biopsy, if possible, because Cimetidine tablets can relieve the symptoms and help the superficial healing of the gastric cancer. The consequences of potential delay in diagnosis should be borne in mind especially in middle aged patients or over, with new or recently changed dyspeptic symptoms.

Due to possible interaction with coumarins, close monitoring of prothrombin time is recommended when cimetidine is concurrently used.

Co-administration of therapeutic agents with a narrow therapeutic index, such as phenytoin or theophylline, may require dosage adjustment when starting or stopping concomitantly administered cimetidine (see Section 4.5).

Lactose: This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Excipients: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

Cimetidine can prolong the elimination of drugs metabolised by oxidation in the liver. Although pharmacological interactions with a number of drugs, e.g. Diazepam, Propranolol, have been demonstrated, only those with oral anticoagulants, phenytoin, theophylline and intravenous lidocaine appear, to date, to be of clinical significance. Close monitoring of patients on Cimetidine receiving oral anticoagulants or phenytoin is recommended and a reduction in the dosage of these drugs may be necessary.

In patients on drug treatment or with illnesses that could cause falls in blood cell count, the possibility that H2 -receptor antagonism could potentiate this effect should be borne in mind.

Cimetidine has the potential to affect the absorption, metabolism or renal excretion of other drugs which is particularly important when drugs with a narrow therapeutic index are administered concurrently. The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment (see Section 4.4).

Interactions may occur by several mechanisms including:

1) Inhibition of certain cytochrome P450 enzymes (including CYP1A2, CYP2C9, CYP2D6 and CYP3A3/A4, and CYP2C18); Inhibition of these enzymes may result in increased plasma levels of certain drugs including warfarin-type coumarin anticoagulants (e.g. warfarin), tricyclic antidepressants (e.g. amitriptyline), class I antiarrhythmics (e.g. lidocaine), calcium channel blockers (e.g. nifedipine, diltiazem), oral sulfonylureas (e.g. glipizide), phenytoin, theophylline and metoprolol.

2) Competition for renal tubular secretion; This may result in increased plasma levels of certain drugs including procainamide, metformin, ciclosporin and tacrolimus.

3) Alteration of gastric pH; The bioavailability of certain drugs may be affected. This can result in either an increase in absorption (e.g. atazanavir) or a decrease in absorption (e.g. some azole antifungals such as ketoconazole, itraconazole or posaconazole).

4) Unknown mechanisms; Cimetidine may potentiate the myelosuppressive effects (e.g. neutropenia, agranulocytosis) of chemotherapeutic agents such as carmustine, fluorouracil, epirubicin, or therapies such as radiation. Isolated cases of clinically relevant interactions have been documented with narcotic analgesics (e.g. morphine).

4.6 Fertility, pregnancy and lactation

Although tests in animals and clinical evidence have not revealed any hazards from the administration of Cimetidine during pregnancy or lactation, both animal and human studies have shown that it does cross the placental barrier and is excreted in breast milk. As with most drugs, the use of Cimetidine should be avoided during pregnancy and lactation unless essential.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Adverse experiences with cimetidine are listed below by system organ class and frequency. Frequencies are defined as: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10000, <1/1000), very rare (<1/10000).

Blood and Lymphatic system disorders:

Uncommon: Leukopenia

Rare: Thrombocytopenia, aplastic anaemia

Very rare: Pancytopenia, agranulocytosis

Immune system disorders:

Very rare: Anaphylaxis. Anaphylaxis is usually cleared on withdrawal of the drug.

Psychiatric disorders

Uncommon: Depression, confusional states, hallucinations. Confusional states, reversible within a few days of withdrawing cimetidine, have been reported, usually in elderly or ill patients.

Nervous system disorders

Common: Headache, dizziness

Cardiac disorders

Uncommon: Tachycardia

Rare: Sinus bradycardia

Very rare: Heart block

Gastrointestinal disorders

Common: Diarrhoea

Very rare: Pancreatitis. Pancreatitis cleared on withdrawal of the drug.

Hepatobiliary disorders

Uncommon: Hepatitis

Rare: Increased serum transaminase levels. Hepatitis and increased serum transaminase levels cleared on withdrawal of the drug.

Skin and subcutaneous tissue disorders

Common: Skin rashes

Very rare: Reversible alopecia and hypersensitivity vasculitis. Hypersensitivity vasculitis usually cleared on withdrawal of the drug.

Musculoskeletal and connective tissue disorders

Common: Myalgia

Very rare: Arthralgia

Renal and urinary disorders

Uncommon: Increases in plasma creatinine

Rare: Interstitial nephritis. Interstitial nephritis cleared on withdrawal of the drug. Small increases in plasma creatinine have been reported, unassociated with changes in glomerular filtration rate. The increases do not progress with continued therapy and disappear at the end of therapy.

Reproductive system and breast disorders

Uncommon: Gynaecomastia and reversible impotence. Gynaecomastia is usually reversible upon discontinuation of cimetidine therapy. Reversible impotence has been reported particularly in patients receiving high doses (e.g. in Zollinger-Ellison Syndrome). However, at regular dosage, the incidence is similar to that in the general population.

Very rare: Galactorrhoea

General disorders and administration site conditions

Common: Tiredness

Very rare: Fever. Fever cleared on withdrawal of the drug.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Acute overdosage of up to 20 grams has been reported several times with no significant ill effects. Induction of vomiting and/or gastric lavage may be employed together with symptomatic and supportive therapy.

Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic Group: H2-receptor Antagonists.

Cimetidine is a histamine H2-receptor antagonist which rapidly inhibits both basal and stimulated gastric secretion of acid and reduces pepsin output. It is a reversible, competitive antagonist, and is used as an anti-ulcer drug. It is highly selective in its action, is virtually without effect on H1 receptors, or indeed on receptors for other autocoids or drugs. Despite the widespread distribution of H2-receptors in the body, Cimetidine interferes remarkably little with physiological functions other than gastric secretion, implying that the extragastric H2-receptors are of minor physiological importance.

However, H2 blockers like Cimetidine do inhibit those effects on the cardiovascular and other systems that are elicited through the corresponding receptors by exogenous or endogenous histamine.

Cimetidine inhibits gastric acid secretion elicited by histamine or other H2 agonists in a dose-dependent, competitive manner; the degree of inhibition parallels the plasma concentration of the drug over a wide range. In addition, the H2 blockers inhibit gastric secretion elicited by muscarinic agonists or by gastrin, although this effect is not always complete.

This breadth of inhibitory effect is not due to non-specific actions at the receptors for these other secretagogues. Rather, this effect, which is non-competitive and indirect, appears to indicate either that these two classes of secretagogues utilise histamine as the final common mediator or, more probably, that ongoing histaminergic stimulation of the parietal cell is important for amplification of the stimuli provided by ACh or gastrin when they act on their own discrete receptors. Receptors for all three secretagogues are present on the parietal cell. The ability of H2 blockers to suppress responses to all three physiological secretagogues makes them potent inhibitors of all phases of gastric acid secretion. Thus these drugs will inhibit basal (fasting) secretion and nocturnal secretion and also that stimulated by food, sham feeding, fundic distension, insulin, or caffeine. The H2 blockers reduce both the volume of gastric juice secreted and its hydrogen ion concentration. Output of pepsin, which is secreted by the chief cells of the gastric glands (mainly under cholinergic control), generally falls in parallel with the reduction in volume of the gastric juice. Secretion of intrinsic factor is also reduced, but it is normally secreted in great excess, and absorption of vitamin B12 is usually adequate even during long-term therapy with H2 blockers.

Concentrations of gastrin in plasma are not significantly altered under fasting conditions; however, the normal prandial elevation of gastrin concentration may be augmented, apparently as a consequence of a reduction in the negative feedback that is normally provided by acid.

5.2 Pharmacokinetic properties

Cimetidine is rapidly and virtually completely absorbed from the gastro-intestinal tract. Absorption is little impaired by food or by antacids. Peak plasma concentrations are obtained about an hour after administration on an empty stomach, and about 2 hours after administration with food. The duration of action is reported to be prolonged by administration with food. Peak concentrations in plasma are attained in about 1 to 2 hours. Hepatic first-pass metabolism results in bioavailabilities of about 60% for Cimetidine. The elimination half-life is about 2-3 hours. Cimetidine is eliminated primarily by the kidneys, and 60% or more may appear in the urine unchanged; much of the rest is oxidation products. Small amounts are recovered in the stools.

Cimetidine crosses the placental barrier and is excreted in milk. It does not readily cross the blood-brain barrier.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

Pharmaceutical particulars

6.1 List of excipients

Core:

Lactose monohydrate

Maize Starch

Magnesium Stearate

Povidone

Sodium starch glycollate

Colloidal anhydrous silica

Tablet Coating:

Hypromellose Titanium dioxide

Quinoline yellow

Iron oxide yellow

Indigo carmine

Polyethylene glycol 400

6.2 Incompatibilities

Not applicable

6.3 Shelf life

3 years

6.4 Special precautions for storage

Tablet container: Do not store above 25°C. Store in the original container. Keep the container tightly closed.

Blister: Do not store above 25°C. Store in the original package. Keep the container in the outer carton.

6.5 Nature and contents of container

Tablet containers (opaque polypropylene containers with polypropylene cap): 100,250,500 and 1000 tablets.

Blister (PVC/aluminium foil blister strips in a carton): 60 and 120 tablets

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Nothing stated.

7.Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com

Cimetidine 200mg Tablets Taj Pharma

Package leaflet – information for the user

Cimetidine 200mg Tablets Taj Pharma

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

Keep this leaflet. You may need to read it
If you have any further questions, ask your doctor or
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section

In this leaflet:

What Cimetidine tablets are and what they are used for
What you need to know before you take Cimetidine tablets
How to take Cimetidine tablets
Possible side effects
How to store Cimetidine tablets
Contents of the pack and other information

1. What Cimetidine tablets are and what they are used for

Cimetidine belongs to a group of medicines called Histamine H2 receptor antagonists and is used as an anti-ulcer drug. It works by reducing the amount of acid in your stomach.

Cimetidine is used to treat and relieve the following conditions:

Ulcers in the stomach (gastric ulcer) and in upper part of the intestine (duodenum ulcer).
Recurrent or stomac ulcers (ulcers that keep coming back or which have occurred following stomach surgery).
Ulcers in the stomach or duodenum which may be caused by non-steroidal anti- inflammatory drugs (NSAIDs, often used to reduce pain, fever and inflammation)
Acid from the stomach escaping into the food pipe causing pain, inflammation and heartburn (oesophageal reflux).
Persistent heartburn and stomach
Upper abdominal pain particularly after
Prevention of internal bleeding from ulcers caused by stress in seriously ill
For patients at risk of acid inhalation before general anaesthesia particularly pregnant women during labour (Mendelson’s syndrome).
Improve absorption of food and reduce fluid loss in short bowel
Reduce the breakdown of pancreatic enzyme supplements in patients with pancreatic problems.
Excess acid in the stomach caused by a tumour in the pancreas (Zollinger-Ellison syndrome).

2. What you need to know before you take Cimetidine tablets Do not take cimetidine tablets:

if you are hypersensitive (allergic) to Cimetidine or to any of the tablet ingredients (see section 6).

Warnings and precautions

Talk to your doctor before taking Cimetidine Tablets:

if you suffer from kidney problems or from gastric
if you are suffering from liver
if you have a history of peptic ulcer, particularly if you are taking a non steroidal anti inflammatory drug (NSAIDs) e.g. aspirin, ibuprofen, naproxen,
if you are middle aged or over, with new or recently changed indigestion symptoms (e.g. Stomach pain or discomfort, heartburn), other causes of your symptoms such as stomach cancer, should be

Other medicines and Cimetidine tablets

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those medicines obtained without a prescription.

In particular, tell your doctor if you are taking any of the following:

Anticoagulants (thin the blood) (e.g. warfarin)
Anticonvulsants (prevent fits) (e.g. phenytoin, diazepam)
Bronchodilators (for breathing difficulties) (e.g. theophylline)
Immunosuppresants (to prevent organ rejection or rheumatism) (e. ciclosporin).
Medicines that cause a fall in blood cell
Antifungals (used to treat fungal infections) (e.g. ketoconazole, itraconazole or posaconazole)
Heart medicines (e.g. diltiazem, nifedipine, lidocaine, propranolol, metoprolol, procainamide or quinidine)
Antidiabetics (lowers glucose levels in the blood) (e.g. metformin or glipizide)
Anti-cancer drugs (treatment of cancer or tumor) (e.g. carmustine, fluorouracil, epirubicin, or therapies such as radiation)
Strong pain killers (e.g. morphine).
Tricyclic antidepressants (used to treat depression) (e.g. amitriptyline).
Antiretroviral drug (used to treat HIV/AIDs) (e.g. atazanavir)
Tacrolimus for eczema

Pregnancy and breast-feeding

It is preferable to avoid the use of Cimetidine Tablets during pregnancy unless it is essential. Tell your doctor if you are pregnant or planning to become pregnant.

Do not take Cimetidine Tablets during breast feeding because cimetidine is excreted in breast milk and can be harmful for your child.

Ask your doctor or pharmacist for advice before taking any other medicine.

Driving and using machines

Cimetidine tablets will not affect your ability to drive or to use machinery.

Important information about some of the ingredients of Cimetidine Tablets:

Cimetidine Tablet contains Lactose monohydrate – If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

Cimetidine tablets contain sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’

3. How to take Cimetidine tablets

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

For oral administration only.

The maximum daily dose of 2.4g (i.e. 2,400mg) should not be exceeded. Dosage should be reduced in patients with kidney problems. Treatment should be given for at least 4 weeks (duodenal ulceration), 6 weeks (benign gastric ulceration) and 8 weeks (ulcer associated with continued non steroidal anti-inflammatory drug). If the ulcer has not healed, your doctor may recommend another course.

Adults:

The usual dose is 400mg twice a day at breakfast and at bedtime or one 200mg tablet three times a day with meals followed by 400mg at bedtime. If inadequate 400mg four times a day with meals and at bedtime.

Your doctor will decide the right dose for you, depending on your condition.

Elderly:

As per adults dosage, unless you have serious kidney problems.

Children over 1 year of age:

“Your doctor will decide the right dose, depending on your child’s weight.”

If you take more Cimetidine tablets than you should

If you or someone else swallows several of these tablets all together, or you think a child has swallowed any of these tablets, contact your doctor or pharmacist or hospital emergency department immediately. Always take any tablets left over with you, also the box and leaflet as this will allow easier identification of the tablets.

If you forget to take Cimetidine tablets

If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose and just carry on as before. Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Possible side effects Like all medicines, cimetidine can cause side-effects, although not everybody gets

Very rarely allergic reactions might occur. If any of the following symptoms occur soon after taking your tablets, stop taking your tablets and tell your doctor immediately.

Rash
itching or hives on the skin
swelling of the face, or other parts of the body
shortness of breath, wheezing or trouble

Some male patients may notice enlarging of the breasts. Very rarely male or female patients may experience unexpected secretion of breast milk. Contact your doctor if these occurs.

The most common side effects are diarrhoea, headache, dizziness, rash or tiredness, muscle pain, joint pain, which are usually mild and do not last long.

Other effects occurring rarely are:

hair loss
mouth ulcers, infections of the throat
fever
kidney problems (symptoms may include changes in the amount of urine passed and its colour, nausea, vomiting, confusion, fever and rash)
confusion (usually in the elderly or ill patients)
A rare type of anaemia in which the red and white blood cells and platelets are all reduced in number (symptoms might include tiredness, being short of breath, looking pale, frequent infections, bruising more easily or nose bleeds)
liver inflammation, which might cause one of the following: nausea (feeling sick), vomiting (being sick), loss of appetite, feeling generally unwell, fever, itching, yellowing of the skin and eyes and dark coloured urine
slowing of heartbeat, irregular heartbeat or fainting
trouble getting or keeping an erection (impotence)
feelings of sadness, depression
hallucinations – seeing/feeling/hearing things that are not
inflammation of the pancreas (sudden onset of abdominal pain, nausea and vomiting) All these side effects should disappear when treatment is

Reporting of side effects

If you get any side effects talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

5. How to store Cimetidine tablets

Do not store above 25°C. Store in the original package. Keep the container tightly closed. Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the carton.

The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information What Cimetidine Tablet contains?

The Active substance in your tablet is Cimetidine.

The Other ingredients are Lactose Monohydrate, Maize Starch, Magnesium Stearate, Povidone K30, Sodium Starch Glycollate, Colloidal anhydrous silica, Hypromellose (E464) Titanium Dioxide, Quinoline Yellow, Iron Oxide Yellow, Indigo Carmine, Polyethylene glycol 400 (see section 2 for Important information about some of the ingredients of Cimetidine tablets).

What Cimetidine Tablet looks like and contents of the pack?

Cimetidine 200mg Tablets are pale green coloured, round, biconvex, film coated, debossed.

Cimetidine 400mg Tablets are pale green coloured, capsule shaped, biconvex, film coated, debossed.

Cimetidine 800mg Tablets are pale green coloured, capsule shaped, biconvex, film coated, debossed.

They are available in container packs of 100, 250, 500 and 1000 tablets and are also available in blister packs of 60,120 (200mg), 30, 60 (400mg) and 30 (800mg) tablets.

(Not all pack sizes may be marketed).

Menu

Cimetidine Tablets USP 800mg Taj Pharma